Your browser doesn't support javascript.
loading
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
Walker, Brian A; Mavrommatis, Konstantinos; Wardell, Christopher P; Ashby, T Cody; Bauer, Michael; Davies, Faith E; Rosenthal, Adam; Wang, Hongwei; Qu, Pingping; Hoering, Antje; Samur, Mehmet; Towfic, Fadi; Ortiz, Maria; Flynt, Erin; Yu, Zhinuan; Yang, Zhihong; Rozelle, Dan; Obenauer, John; Trotter, Matthew; Auclair, Daniel; Keats, Jonathan; Bolli, Niccolo; Fulciniti, Mariateresa; Szalat, Raphael; Moreau, Philippe; Durie, Brian; Stewart, A Keith; Goldschmidt, Hartmut; Raab, Marc S; Einsele, Hermann; Sonneveld, Pieter; San Miguel, Jesus; Lonial, Sagar; Jackson, Graham H; Anderson, Kenneth C; Avet-Loiseau, Herve; Munshi, Nikhil; Thakurta, Anjan; Morgan, Gareth J.
Afiliação
  • Walker BA; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR.
  • Mavrommatis K; Celgene Corporation, San Francisco, CA.
  • Wardell CP; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR.
  • Ashby TC; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR.
  • Bauer M; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR.
  • Davies FE; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR.
  • Rosenthal A; Cancer Research and Biostatistics, Seattle, WA.
  • Wang H; Cancer Research and Biostatistics, Seattle, WA.
  • Qu P; Cancer Research and Biostatistics, Seattle, WA.
  • Hoering A; Cancer Research and Biostatistics, Seattle, WA.
  • Samur M; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Towfic F; Celgene Corporation, Summit, NJ.
  • Ortiz M; Celgene Institute of Translational Research Europe, Sevilla, Spain.
  • Flynt E; Celgene Corporation, Summit, NJ.
  • Yu Z; Celgene Corporation, Summit, NJ.
  • Yang Z; Celgene Corporation, Summit, NJ.
  • Rozelle D; Rancho BioSciences, San Diego, CA.
  • Obenauer J; Rancho BioSciences, San Diego, CA.
  • Trotter M; Celgene Institute of Translational Research Europe, Sevilla, Spain.
  • Auclair D; Multiple Myeloma Research Foundation, Norwalk, CT.
  • Keats J; Translational Genomics Research Institute, Phoenix, AZ.
  • Bolli N; Department of Oncology, University of Milan, Milan, Italy.
  • Fulciniti M; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Szalat R; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Moreau P; Department of Hematology, University of Nantes, Nantes, France.
  • Durie B; Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA.
  • Stewart AK; Department of Hematology, Mayo Clinic, Scottsdale, AZ.
  • Goldschmidt H; Department of Medicine V, Hematology and Oncology, University Hospital of Heidelberg, Heidelberg, Germany.
  • Raab MS; Department of Medicine V, Hematology and Oncology, University Hospital of Heidelberg, Heidelberg, Germany.
  • Einsele H; German Cancer Research Center, Heidelberg, Germany.
  • Sonneveld P; Department of Internal Medicine II, Wurzburg University, Wurzburg, Germany.
  • San Miguel J; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Lonial S; Centro Investigacion Medica Aplicada, Clinica Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Oncología, Pamplona, Spain.
  • Jackson GH; Winship Cancer Institute, Emory University, Atlanta, GA.
  • Anderson KC; Department of Haematology, Newcastle University, Newcastle, United Kingdom.
  • Avet-Loiseau H; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Munshi N; Centre de Recherche en Cancérologie de Toulouse Institut National de la Santé et de la Recherche Médicale U1037, Toulouse, France; and.
  • Thakurta A; L'Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire, Toulouse, France.
  • Morgan GJ; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Blood ; 132(6): 587-597, 2018 08 09.
Article em En | MEDLINE | ID: mdl-29884741
ABSTRACT
Understanding the profile of oncogene and tumor suppressor gene mutations with their interactions and impact on the prognosis of multiple myeloma (MM) can improve the definition of disease subsets and identify pathways important in disease pathobiology. Using integrated genomics of 1273 newly diagnosed patients with MM, we identified 63 driver genes, some of which are novel, including IDH1, IDH2, HUWE1, KLHL6, and PTPN11 Oncogene mutations are significantly more clonal than tumor suppressor mutations, indicating they may exert a bigger selective pressure. Patients with more driver gene abnormalities are associated with worse outcomes, as are identified mechanisms of genomic instability. Oncogenic dependencies were identified between mutations in driver genes, common regions of copy number change, and primary translocation and hyperdiploidy events. These dependencies included associations with t(4;14) and mutations in FGFR3, DIS3, and PRKD2; t(11;14) with mutations in CCND1 and IRF4; t(14;16) with mutations in MAF, BRAF, DIS3, and ATM; and hyperdiploidy with gain 11q, mutations in FAM46C, and MYC rearrangements. These associations indicate that the genomic landscape of myeloma is predetermined by the primary events upon which further dependencies are built, giving rise to a nonrandom accumulation of genetic hits. Understanding these dependencies may elucidate potential evolutionary patterns and lead to better treatment regimens.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oncogenes / Regulação Neoplásica da Expressão Gênica / Mutagênese / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Argentina

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oncogenes / Regulação Neoplásica da Expressão Gênica / Mutagênese / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Argentina